Healthcare
The Future of Brain-Computer Interfaces: How AI-Powered Implants Could Transform Human Health
03 Nov 2026
Chinese neurotechnology company NeuroXess has raised RMB 700 million to advance its wireless brain-computer interface technology, as new clinical research demonstrates how AI-powered implants could help people with paralysis communicate, use digital devices and regain independence.
London, 3 November 2026 – Brain-computer interface (BCI) technology is attracting growing investment as researchers develop systems capable of translating brain activity into commands for computers, communication devices and assistive technologies. On 28 October 2026, Shanghai-based NeuroXess announced the completion of a RMB 700 million (approximately $98 million) Series B funding round to advance its fully implantable, wireless brain-computer interface system.
The investment comes amid significant advances in neurotechnology research, including clinical studies demonstrating how implanted brain sensors and artificial intelligence can help people with severe paralysis communicate and operate computers. While most of these systems remain experimental, recent results suggest that brain-computer interfaces are progressing beyond controlled laboratory demonstrations towards longer-term use in everyday environments.
NeuroXess Raises RMB 700 Million to Advance Brain Implant Technology
NeuroXess, founded in 2021, is developing flexible implantable electrodes and wireless systems designed to record neural activity and translate it into digital commands. Its latest funding round was jointly led by SDIC Juli, Shenzhen Capital Group and Qinzhi Capital, with participation from investors including IDG Capital and several semiconductor and healthcare investment firms.
According to the company, the funding will support multicentre clinical trials, regulatory approval procedures, manufacturing expansion and the development of next-generation brain-computer interfaces. NeuroXess is also exploring how its technology can work alongside AI systems to enable more sophisticated interaction with external devices.
The company's flagship system, known as Triple-F, is designed around three capabilities: full implantation, wireless operation and support for multiple functions. The system uses flexible electrodes placed on the surface of the brain beneath the dura mater, while other components are implanted beneath the skin. Wireless technology allows neural information to be transmitted without a permanent cable passing through the skin.
NeuroXess reported that its technology had been used in 65 clinical cases and that a registration clinical trial involving nearly 20 hospitals began in July 2026. The company is also developing a 14,300-square-metre manufacturing facility with a planned annual production capacity of 10,000 systems. These manufacturing figures represent future capacity targets rather than approved devices already available to patients.
How AI Translates Brain Signals into Digital Commands
Brain-computer interfaces establish a communication pathway between neural activity and external technology. Sensors detect patterns associated with attempted speech, movement or other actions, while algorithms analyse these signals and translate them into commands that computers and connected devices can understand.
Artificial intelligence is important because neural signals vary between individuals and can change over time. Machine-learning models are trained to recognise relationships between brain activity and intended actions, allowing users to interact with digital systems even when injuries or neurological conditions prevent them from moving or speaking normally.
NeuroXess has demonstrated applications combining its brain-computer interface with AI-powered smart glasses and connected devices. In one company-reported demonstration, a participant used visual information from smart glasses alongside brain signals to select and control equipment, including a hospital bed and lighting.
Such applications could eventually support people living with spinal cord injuries, advanced neurological disorders or severe physical disabilities. However, the ability to recognise a participant's intended command in a controlled demonstration does not establish that the same system will perform reliably across different patients and everyday situations.
Clinical Research Shows Progress in Restoring Communication
Separate research published in Nature Medicine in June 2026 demonstrated the potential of brain-computer interfaces for long-term independent use. Scientists reported that a man living with amyotrophic lateral sclerosis (ALS), a progressive neurological disease, used an implanted interface to communicate and control a computer from home over approximately 19 months.
The participant used the system for more than 3,800 hours without researchers being present during daily operation. During the study, he communicated 183,060 sentences, totalling almost two million words, at an average rate of 56 words per minute. He rated 92% of sentences as at least mostly correct, while structured testing demonstrated word accuracy above 99% using a vocabulary of more than 125,000 words.
The participant was also able to send messages, browse the internet and continue working. Researchers said the results demonstrated that brain-computer interfaces could support sustained communication outside laboratory settings, although the study involved a single individual and required assistance from caregivers for certain setup activities.
Further progress was reported in September 2026, when researchers at the University of California, San Francisco, published findings in Nature Neuroscience demonstrating simultaneous decoding of speech and gestures. The system used brain implants and machine-learning algorithms to translate neural activity into spoken communication and movements performed by a digital avatar.
Researchers tested neural decoding in three participants with paralysis, with two participants using parallel systems to control speech and gestures through an avatar. The findings represent progress towards communication tools that could reproduce more natural human expression, including the gestures that accompany conversation.
Clinical Safety, Data Privacy and Accessibility Remain Challenges
Despite encouraging results, implantable brain-computer interfaces involve medical and technical risks that require careful evaluation. Surgical procedures may carry risks of infection, bleeding and tissue injury, while implanted electrodes must remain functional and compatible with surrounding tissue over extended periods.
Long-term performance also remains a challenge. Neural signals can change as electrodes shift, tissues respond to implants or users adapt their behaviour. AI systems must therefore maintain accuracy without requiring constant recalibration, especially when patients depend on the technology for communication and essential activities.
Neural data introduces additional privacy considerations. Information recorded from the brain is highly sensitive, and healthcare organisations will need safeguards covering data storage, access permissions, cybersecurity and the use of neural recordings to train AI models.
Cost and accessibility may also determine how widely the technology is adopted. Implantable systems require specialist medical teams, follow-up care and technical support, potentially limiting access even if clinical trials demonstrate safety and effectiveness.
From Experimental Implants to Everyday Healthcare
The latest developments from NeuroXess and academic research institutions show how brain-computer interfaces are progressing through investment, clinical testing and improvements in AI-based neural decoding.
For people living with severe paralysis, the potential benefits are substantial. The ability to communicate independently, operate digital devices or control elements of their environment could improve daily autonomy and participation in education, employment and social activities.
However, large-scale adoption will require more than successful demonstrations. Researchers must establish long-term safety, demonstrate consistent results across larger patient populations and determine how these technologies can be delivered within healthcare systems.
NeuroXess's RMB 700 million investment provides additional resources for that process, while recent clinical studies offer evidence that some brain-computer interfaces can already support meaningful activities outside research laboratories. Whether these advances lead to widely available medical treatments will depend on the outcomes of ongoing trials, regulatory assessments and the ability to make the technology reliable and accessible for patients.
Sources
1. NeuroXess – Official Company News (28 October 2026)
https://www.neuroxess.com/news/
2. TechNode – Brain-Computer Interface Startup NeuroXess Raises RMB 700 Million in Series B Funding (28 October 2026)
https://technode.com/2026/10/28/brain-computer-interface-startup-neuroxess-raises-rmb-700-million-in-series-b-funding/
3. 36Kr – NeuroXess Secures 700 Million Yuan Series B Financing (28 October 2026)
https://eu.36kr.com/en/p/4043628160685189
4. Nature Medicine – Long-Term Independent Use of an Intracortical Brain–Computer Interface for Speech and Cursor Control (15 June 2026)
https://www.nature.com/articles/s41591-026-04414-6
5. Nature Neuroscience – Simultaneous Speech and Gesture Decoding for Multimodal Communication in Paralysis (14 September 2026)
https://doi.org/10.1038/s41593-026-02446-2
6. National Institutes of Health – Neuroprosthesis for Paralysis Enables Simultaneous Speech and Body Language (14 September 2026)
https://www.nih.gov/news-events/news-releases/neuroprosthesis-paralysis-enables-simultaneous-speech-body-language
